Skip to content

The FDA Just Approved the First Drug That Can Functionally Cure Chronic Hepatitis B

October 30, 2026
The FDA Just Approved the First Drug That Can Functionally Cure Chronic Hepatitis B

Medicine & Healthcare

By TrendScope Daily Team · October 30, 2026

Share Facebook X WhatsApp LinkedIn Copy Link

For nearly forty years, a diagnosis of chronic hepatitis B has come with the same quiet sentence: you will likely take an antiviral pill, every day, for the rest of your life, to keep the virus suppressed but never gone. On October 20, the U.S. Food and Drug Administration approved the first drug designed to change that. Hibsago (bepirovirsen), developed by GSK, is a first-in-class antisense oligonucleotide that gave a meaningful share of patients in late-stage trials a shot at what hepatologists call a “functional cure” — durable viral control without lifelong medication.

How an Antisense Drug Attacks the Virus Differently

Standard hepatitis B treatment relies on nucleos(t)ide analogues — pills like tenofovir or entecavir — that block the virus from replicating but do nothing to clear the viral genetic material already lodged inside liver cells. Stop the pills, and the virus typically rebounds. Bepirovirsen works on a different part of the problem: it is a short synthetic strand of genetic material that binds to and degrades the viral mRNA responsible for producing hepatitis B surface antigen (HBsAg), a protein that helps the virus evade the immune system. By silencing that signal, the drug appears to let a patient’s own immune response re-engage and, in some cases, bring the infection under lasting control.

Inside the B-Well Trials

The approval rests on two global Phase 3 trials, B-Well 1 and B-Well 2, run across 29 countries and enrolling adults with chronic hepatitis B who were already on suppressive antiviral therapy. Patients received a six-month course of bepirovirsen, administered by injection with the option to self-administer after the first dose, on top of their existing treatment. The primary endpoint — functional cure, defined as sustained loss of detectable virus and surface antigen six months after all therapy stopped — was reached by 19% of the 1,220 patients who received bepirovirsen, compared with 0% of the 614 patients on placebo. Among the roughly 45% of patients with lower baseline antigen levels (HBsAg of 1,000 IU/mL or below), the functional cure rate rose to 26%, again against 0% for placebo. By contrast, standard antiviral therapy alone typically produces a functional cure in under 1% of patients even after a full year of treatment.

“This is the start of a new era in treating people living with chronic hepatitis B. Bepirovirsen offers patients the potential to achieve functional cure after a short period of treatment, a long-standing goal for patients and physicians alike.”

— Dr. Norah Terrault, Chief of Gastroenterology & Hepatology, USC Keck Medical Center

A Disease That Quietly Drives Liver Cancer Worldwide

Chronic hepatitis B affects more than 240 million people globally and an estimated 1.7 million in the United States, according to figures GSK cited alongside the approval, and the infection is linked to roughly 1.1 million deaths each year, mostly from the cirrhosis and liver cancer it can cause over decades. The Hepatitis B Foundation says the virus accounts for approximately 56% of liver cancer cases worldwide, making it one of the most consequential chronic infections most Americans rarely hear about. “CHB is a major public health challenge, affecting millions of people in the US and accounting for approximately 56% of all global liver cancer cases,” said Dr. Chari Cohen, president of the Hepatitis B Foundation, adding that the approval “marks significant progress towards our aim of transforming the way CHB is managed.”

Who Qualifies, and What Comes Next

Hibsago isn’t for everyone with hepatitis B. The approved label covers adults without cirrhosis who have been on antiviral therapy for at least six months, have suppressed HBV DNA, and have surface antigen levels at or below 3,000 IU/mL, measured using a companion diagnostic, Roche’s Elecsys HBsAg II quant II assay, to confirm eligibility. Patients continue their antiviral pills for at least 24 weeks after their final bepirovirsen injection. The trials turned up no new safety signals, though the label carries a boxed warning for serious liver reactions and low platelet counts, alongside more common side effects like injection-site pain, fever, fatigue, and headache. GSK said bepirovirsen has also been approved in Japan, with additional regulatory decisions expected in other countries in the coming months. “For the first time, with Hibsago, US patients have the potential to achieve functional cure,” said Tony Wood, GSK’s chief scientific officer.

Patients newly navigating a chronic hepatitis B diagnosis, or trying to understand how a drug like this fits into long-term care, often start with a plain-language reference alongside conversations with their own hepatologist. A patient guide to hepatitis B and liver health can be a useful starting point for framing questions to bring to that appointment.

As an Amazon Associate, TrendScope Daily earns from qualifying purchases made through links in this article.

Quick questions

What is Hibsago?

Hibsago (bepirovirsen) is GSK’s antisense drug for chronic hepatitis B, approved by the FDA on October 20.

Can Hibsago cure hepatitis B?

It can produce a ‘functional cure’ in some patients; about 19% reached it in trials, so most will still need ongoing treatment.

How is Hibsago different from tenofovir or entecavir?

Those pills block viral replication, while bepirovirsen degrades viral mRNA inside liver cells. Patients should discuss options with their doctor.

Related on TrendScope Daily


Bottom Line

Hibsago won’t replace daily antiviral pills for most of the roughly 1.7 million Americans living with chronic hepatitis B, and a 19% functional cure rate means the majority of patients who try it will still need ongoing treatment. But against a standard of care that rarely clears the infection at all, it’s the first real evidence that a defined course of therapy — rather than a lifetime of pills — can be a realistic goal for a meaningful subset of patients. Expect hepatologists to begin screening eligible patients for surface antigen levels in the coming months, and watch for GSK’s pending decisions in other countries as a signal of how quickly this approach spreads beyond the U.S.

Share Facebook X WhatsApp LinkedIn Copy Link